tiakis Biotech Successfully Completes Data Package to Advance Tiprelestat into Phase II clinical trial in PAH
— 6-month GLP-tox study reinforces favorable safety profile of Tiprelestat
— Phase II Study in Pulmonary Arterial Hypertension (PAH) to be initiated by Stanford University in mid-2026
tiakis Biotech AG (“tiakis”), a clinical-stage biopharmaceutical company developing novel therapeutics for life-threatening pulmonary and cardiovascular diseases, today announced that the Company has successfully finalized a comprehensive data package to advance Tiprelestat into a Phase II clinical trial in Pulmonary Arterial Hypertension (PAH) by completing a preclinical GLP-tox study.
Captain T Cell Closes Financing Round to Advance its Proprietary, Next-Generation TCR-T Pipeline Into the Clinic
- Available funding totaling EUR 20 million dedicated to developing novel solid tumor treatments addressing a high unmet medical need
- Springboard Health Angels, Pluton Asset Holding AG, Sintra Limited, and Technologiegründerfonds Sachsen joined as new investors
- Existing investors i&i Biotech Fund I SCSp, HIL-INVENT and Brandenburg Kapital also participated in the round
Captain T Cell, a biotechnology company developing next-generation TCR-T cell therapies for solid tumors, today announced the successful closing of an equity financing round with both new and existing investors. The latest equity funding, along with already secured grants, provides Captain T Cell with a total budget of EUR 20 million to advance its best-in-class autologous program CTC127 to clinical Phase I read-outs and its first-in-class allogeneic program for off-the-shelf solid tumor treatments towards clinical trial readiness.
selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of-Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease
- Disease modifying mechanism of action: short treatment course results in significant and durable clinical response in psoriasis patients
- si-544 is the first highly potent and selective Kv1.3 blocker to safely achieve patient plasma levels suitable for high target engagement
- Excellent safety and tolerability consistent with prior clinical experience; no dose-limiting toxicities and no serious safety signals observed
- Full immunocompetence maintained in si-544 treated patients; no immunosuppression
selectION, Inc. (“selectION” or the “Company”), a clinical-stage biopharmaceutical company developing novel treatments for T cell-mediated autoimmune diseases, today announced the successful completion of its phase 1b proof-of-concept trial evaluating si-544, a first-in-class Kv1.3 blocker in patients diagnosed with psoriasis vulgaris.
